HeatherJLandauMD

Assistant Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Landau

Dr. Heather Landau is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from SUNY Upstate Medical University and has been in practice 16 years. Dr. Landau accepts several types of health insurance, listed below. She is one of 495 doctors at Memorial Sloan Kettering Cancer Center and one of 90 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(415) 805-7761

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
University of ColoradoResidency, Internal Medicine, 2001 - 2004
SUNY Upstate Medical UniversityClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NJ State Medical License 2021 - 2025
NY State Medical License 2003 - 2025
NH State Medical License 2024 - 2024
CO State Medical License 2003 - 2005

Clinical Trials

Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma Start of enrollment: 2006 Nov 01
Completed
Phase 2
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis Start of enrollment: 2007 Feb 01
Completed
Phase 2
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma Start of enrollment: 2007 Nov 01
Terminated
Phase 2
Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L Start of enrollment: 2008 Dec 10
Completed
Phase 2
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Start of enrollment: 2013 Jan 01
Completed
Phase 2
Telemedicine Evaluation for Stem Cell Transplant Patients Start of enrollment: 2011 Mar 01
Completed
Not Applicable
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis Start of enrollment: 2011 Jun 24
Completed
Not Applicable
Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant Start of enrollment: 2011 Aug 01
Completed
Not Applicable
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2013 Apr 01
Completed
Phase 1, Phase 2
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis Start of enrollment: 2013 Feb 01
Completed
Phase 1
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2016 Mar 01
Completed
Phase 2
Pilot Trial of Homebound Stem Cell Transplantation Start of enrollment: 2016 Jan 01
Recruiting
Not Applicable
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. Start of enrollment: 2016 Sep 01
Active, not recruiting
Phase 1
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis Start of enrollment: 2017 Jun 12
Completed
Phase 1, Phase 2
Ixazomib Maintenance Study in Patients With AL Amyloidosis Start of enrollment: 2018 Aug 02
Active, not recruiting
Phase 2
Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) Start of enrollment: 2022 Apr 26
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Te...
Marcelo C Pasquini, Paul K Wallace, Brent Logan, Manmeet Kaur, Joseph D Tario
Journal of Clinical Oncology. 2024-08-10
7 citations
Cancer-testis antigen expression and immunogenicity in AL amyloidosis
Michael Rosenzweig, Heather Landau, David C. Seldin, Carl O'Hara, Saulius Girnius
Blood Cancer Journal. 2012-09-14
18 citations
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
Sandy W. Wong, Ute Hegenbart, Giovanni Palladini, Gunjan L. Shah, Heather Landau
Clinical Lymphoma, Myeloma & Leukemia. 2018-11-01

Journal Articles

Novel Iatrogenic Amyloidosis Caused by Peptide Drug Liraglutide: A Clinical Mimic of AL Amyloidosis
Heather J Landau, Ahmet Dogan, Haematologica

Abstracts/Posters

A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
Heather J Landau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus PhysicianÍs Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary...
Heather J Landau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage ...
Heather J Landau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
Heather J Landau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Genomic Landscape of Sex Disparities in Multiple Myeloma
Heather J Landau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) ...
Heather J Landau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
Heather J Landau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
Heather J Landau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
Heather J Landau, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Untangling Amyloidosis 2019
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Dysgeusia Is Associated with Higher Melphalan Pharmacokinetic Levels and Results in Poorer Caloric Intake and Worse Symptom Burden after Autologous Stem Cell Transplan...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of CD34 Cell Dose Infused on the Duration of Absolute Neutropenia after High Dose Melphalan and Autologous HCT for Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Tom Brokaw: Cancer Interrupts His Lucky LifeNovember 13th, 2015
Emerging Concepts in Multiple MyelomaOctober 29th, 2015
A Study to Identify Barriers to Cellular Therapies for People with Plasma Cell DisordersNovember 14th, 2023
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS California CaliforniaCare HMO
BCBS California PowerSelect HMO
BCBS California PPO
BCBS Florida BlueCare HMO
BCBS Florida BlueSelect
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
Blue Shield CA Local Access Plus HMO
Blue Shield California HMO
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Health Net California Large Group PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PHCS PPO - Kaiser
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
Pacificare HMO
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment